-
Groundbreaking Clinical Results for Intranasal Foralumab Published by Tiziana Life Sciences
NASDAQ: $TLSA Tiziana Life Sciences plc recently announced a significant milestone in their ongoing research and development efforts: the peer-reviewed publication of clinical study results concerning their lead product candidate, intranasal Foralumab. This publication, detailed in a press release issued on January 20, 2026, marks a crucial step forward in validating the potential of this…
-
RenovoRx’s RenovoCath System Gains Traction: Expanding to Nine Leading Cancer Centers
NASDAQ: $RNXT The landscape of localized cancer treatment is witnessing significant evolution, and RenovoRx, Inc. is at the forefront of this shift. A recent announcement highlights a major milestone for the company: the expansion of the commercial adoption of its innovative RenovoCath® system across nine active cancer centers in the United States. This expansion signifies…
-
Nxera Pharma Announces Promising Phase 3 Trial Results for Daridorexant in South Korea
The pharmaceutical landscape received exciting news recently following the announcement from Nxera Pharma regarding the positive outcomes of its Phase 3 clinical trial for Daridorexant, conducted specifically in South Korea. This development marks a significant step forward in making a potentially transformative treatment option available to patients suffering from insomnia in the region. Understanding the…
-
Significant Clinical Milestone: FDA Acknowledges Positive Outcomes for Rexlemestrocel-L in Chronic Back Pain Management
NASDAQ: $MESO A Promising Advancement in Treating Chronic Back Pain The recent announcement from Mesoblast regarding the clinical data for Rexlemestrocel-L represents a noteworthy step forward in addressing the pervasive challenge of chronic back pain. According to the news release dated January 19, 2026, the U.S. Food and Drug Administration (FDA) has formally acknowledged the…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 01-18-2026 TO 01-24-2026
We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock quote page…
$ABBV, $AZN, $ELDN, $GMAB, $GNLX, $LLY, $LTRN, $MNKD, $NOV, $NVO, $NVS, $PFE, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases -
Clene’s Upcoming Presentation at the Emerging Growth Conference: What Investors Should Know
NASDAQ: $CLNN Clene Inc., a clinical-stage company focused on developing treatments that target neurodegeneration and inflammation, has announced its participation in a significant industry event. The company is scheduled to present at the Emerging Growth Conference, as detailed in their recent press release. The Significance of the Emerging Growth Conference The Emerging Growth Conference (EGC)…
-
A Significant Step Forward: First U.S. Patient Enrolled in BiPASS Phase 3 Study for Prostate Cancer Diagnosis
NASDAQ: $TLX Today marks an important milestone in the ongoing effort to improve the diagnosis and management of prostate cancer. We are excited to share news regarding the initiation of dosing for the first U.S. patient in the pivotal BiPASS Phase 3 clinical trial. This study focuses on assessing the performance of a novel diagnostic…
-
Exciting Progress: Corvus Pharmaceuticals Poised to Share Promising Data on Soquelitinib for Atopic Dermatitis
NASDAQ: $CRVS Pharmaceutical research is a journey of meticulous steps, and today, the spotlight shines brightly on Corvus Pharmaceuticals as they prepare to share significant updates from their ongoing clinical investigations. Specifically, the market and the patient community are eagerly anticipating the forthcoming announcement regarding the results from Cohort 4 of the placebo-controlled Phase 1…
-
Abpro’s ABP-102 Takes Center Stage at J.P. Morgan Healthcare Conference via Celltrion Presentation
NASDAQ: $ABP The recent announcement surrounding Abpro Therapeutics’ lead product candidate, ABP-102, has generated considerable excitement within the biotechnology sector. According to a press release published on GlobeNewswire, details regarding this promising program were prominently featured during a presentation by Celltrion Healthcare Co., Ltd. at the prestigious 44th Annual J.P. Morgan Healthcare Conference. For those…
-
Ascentage Pharma Shares Vision for Global Expansion at J.P. Morgan Conference
NASDAQ: $AAPG The recent 44th Annual J.P. Morgan Healthcare Conference served as a pivotal stage for Ascentage Pharma to articulate its comprehensive strategy for worldwide growth and innovation. The company, a dynamic force in the biopharmaceutical sector, used its presentation slot to detail how it plans to propel its pipeline from clinical promise to global…